Overview of the model. The Markov model has 6 general categories of health states that reflect the stage of hepatitis C virus (HCV)–associated liver disease. Each health state is stratified by CD4 cell count and treatment status with highly active antiretroviral therapy. Death may be caused by a human immunodeficiency virus (HIV)–related illness, HCV-related liver failure or cancer, or other causes. See the "Methods" section for details.
One-way sensitivity analyses of selected model input variables. The impact on the incremental cost-effectiveness ratio of 48 weeks of combination therapy with pegylated interferon alfa and ribavirin in coinfected patients with genotype 1 (compared with 48 weeks of interferon alfa and ribavirin therapy) (A) and of 48 weeks of interferon alfa and ribavirin therapy in coinfected patients with non-1 genotypes (compared with 24 weeks of combination therapy) (B). The dashed lines show the base case values, and the horizontal bars represent the range of incremental cost-effectiveness ratios resulting from varying each variable over its plausible range. HCV indicates hepatitis C infection; HAART, highly active antiretroviral therapy.
One-way sensitivity analyses of the relative risk of progression to cirrhosis in coinfected patients compared with human immunodeficiency virus (HIV)–uninfected patients. A, The effect of varying the relative risk between 1 and 5 in patients with genotype 1 on the incremental cost-effectiveness ratio of different treatment strategies for mild and moderate chronic hepatitis C virus (HCV). B, The effect of varying the relative risk between 1 and 5 in patients with non-1 genotypes on the incremental cost-effectiveness ratio of different treatment strategies for mild and moderate chronic HCV. Peg indicates pegylated interferon alfa; IFN, interferon alfa; Rib, ribavirin; and QALY, quality-adjusted life-year.
Kuehne FC, Bethe U, Freedberg K, Goldie SJ. Treatment for Hepatitis C Virus in Human Immunodeficiency Virus–Infected PatientsClinical Benefits and Cost-effectiveness. Arch Intern Med. 2002;162(22):2545-2556. doi:10.1001/archinte.162.22.2545
Hepatitis C virus (HCV) is an important cause of liver disease in human immunodeficiency virus (HIV)–infected patients.
To assess the cost-effectiveness of alternative management strategies for chronic HCV in co-infected patients with moderate hepatitis.
A state-transition model was used to simulate a cohort of HIV-infected patients with a mean CD4 cell count of 350 cells/µL and moderate chronic hepatitis C stratified by genotype. Strategies included interferon alfa (48 weeks), pegylated interferon alfa (48 weeks), interferon alfa and ribavirin (24 and 48 weeks), pegylated interferon alfa and ribavirin (48 weeks), and no treatment. Outcomes included life expectancy, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios.
Treatment for moderate chronic HCV with combination therapy using an interferon-based regimen reduced the incidence of cirrhosis and provided gains in quality-adjusted life expectancy ranging from 6.2 to 13.9 months, depending on genotype. Regardless of genotype, the cost-effectiveness of interferon alfa and ribavirin for patients with moderate hepatitis was lower than $50 000 per QALY vs the next best strategy. With genotype 1, pegylated interferon alfa (vs interferon alfa) and ribavirin therapy provided an additional 1.6 quality-adjusted life-months for $40 000 per QALY. Because treatment is more effective with non-1 genotypes, pegylated interferon (vs interferon alfa) and ribavirin provided only 3 additional quality-adjusted life-months for $105 300 per QALY. For patients who were intolerant of ribavirin, monotherapy with pegylated interferon was always the most cost-effective option.
Combination therapy for moderate hepatitis in coinfected patients will increase quality-adjusted life expectancy and have a cost-effectiveness ratio comparable to that of other well-accepted clinical interventions.
APPROXIMATELY ONE third of all human immunodeficiency virus (HIV)–infected persons in the United States are coinfected with hepatitis C virus (HCV).1- 3 Although the prognosis for HIV infection has improved dramatically with the availability of highly active antiretroviral therapy (HAART),4,5 coinfected patients are now vulnerable to the complications associated with long-term HCV infection (eg, cirrhosis).6- 9 Numerous studies10- 20 report an increase in hospital admissions and deaths due to liver disease in HIV-infected patients. Compared with HIV-uninfected patients, coinfected patients have higher levels of HCV RNA21- 25 and a greater risk of progression to severe liver disease.2,6,7,19,24- 39 Hepatitis C virus may also have a negative impact on HIV disease progression, although this issue remains controversial.2,19,38,40- 45
Clinical trials46- 52 have documented the enhanced antiviral efficacy of combination therapy with ribavirin and interferon alfa, with sustained treatment responses ranging from 33% to 49%. Moreover, multiple studies53- 63 focusing on HIV-uninfected patients have shown that the cost-effectiveness of treatment for chronic HCV is comparable to that of other well-accepted standard preventive interventions. Recently, treatment with pegylated interferon alfa (with and without ribavirin), a long-acting variant of interferon alfa that requires less frequent dosing, has been shown to have higher efficacy than use of interferon alfa alone.64- 70 The cost-effectiveness of pegylated interferon alfa therapy has not yet been explored in either HIV-infected or HIV-uninfected patients.
The longer expected survival of HIV-infected patients receiving HAART, coupled with the potentially accelerated progression of HCV-related liver disease, has resulted in a set of complex clinical and policy questions. Treatment recommendations for HIV-uninfected patients may not be directly applicable to coinfected patients.71- 75 Although information from ongoing clinical studies in coinfected patients is anticipated in the next several years, the ideal source of data—long-term placebo-controlled trials of all potential treatment strategies—is not likely to be feasible. For many coinfected patients, treatment decisions must be made now, in the setting of considerable uncertainty and despite the absence of perfect information. To inform these decisions, we incorporated the best available data to assess the health and economic consequences of a variety of strategies to manage HCV-related liver disease in HIV-infected patients.
A computer-based mathematical model was used to compare the following strategies for the management of moderate chronic HCV in coinfected patients with CD4 cell counts greater than 350 cells/µL: (1) no HCV treatment, (2) monotherapy with interferon alfa (48 weeks), (3) monotherapy with pegylated interferon alfa (48 weeks), (4) combination therapy with interferon alfa and ribavirin (24 and 48 weeks), and (5) combination therapy with pegylated interferon alfa and ribavirin (48 weeks). Analyses were stratified by HCV genotype because distributions of genotypes vary in different patient subgroups and affect response to therapy.64,65,76 We adopted a societal perspective and followed the recommendations of the Panel on Cost-effectiveness in Health and Medicine.77 Model outcomes included quality-adjusted life expectancy (QALE) and total lifetime costs. Comparative performance of alternative strategies was measured by the incremental cost-effectiveness ratio, defined as the additional cost of a specific treatment strategy divided by its additional clinical benefit compared with the next least-expensive strategy. We conducted univariate and multivariate sensitivity analyses to assess variable uncertainty, and we explored the effect of alternative assumptions compared with those made in the base case.
A deterministic state-transition Markov model (DATA 3.5; TreeAge Software Inc, Williamstown, Mass) was used to simulate the natural history of HCV-induced liver disease in coinfected patients (Figure 1). Health states were defined to reflect 5 broad categories of HCV-related liver disease (mild chronic HCV, moderate chronic HCV, compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma [HCC]), stage of HIV disease (CD4 cell count >500, 200-500, and <200 cells/µL), and treatment status with HAART. Decompensated cirrhosis was defined as the presence of complications of portal hypertension, such as ascites, variceal bleeding, or hepatic encephalopathy.
In the base case, a cohort of coinfected individuals entered the model with a mean CD4 cell count of 350 cells/µL and histologically moderate chronic hepatitis. Transition probabilities from the literature were used to move individuals through different health states over time. The time horizon of the analysis was divided into equal increments during which patients could progress to later stages of HCV or HIV. Each month, patients could progress from mild to moderate hepatitis or from moderate hepatitis to cirrhosis. Patients with cirrhosis could develop complications (ie, decompensated cirrhosis) or primary HCC. In the absence of HAART, patients could progress from higher to lower CD4 cell strata. We conservatively assumed that HIV progression was independent of HCV but explored the implications of a more rapid progression to acquired immunodeficiency syndrome. Each month, patients faced competing mortality risks from advanced liver disease, acquired immunodeficiency syndrome, and other causes.
We made the following assumptions: (1) HCV treatment was discontinued in patients not responding to monotherapy after 3 months or combination therapy after 6 months71,72,74; (2) HCV treatment resulted in 1 of 3 potential outcomes—no treatment response, a partial but nonsustained response, or a sustained response; (3) patients with no treatment response received no clinical benefit and were subject to their annual pretreatment risk of HCV-related liver disease progression; (4) patients with a partial but nonsustained response did not progress in their HCV-related liver disease during treatment but were subject to pretreatment risks of liver disease once treatment was stopped; (5) patients with a sustained response (ie, undetectable HCV RNA for >6 months after treatment) did not experience a future risk of HCV-related liver disease, although the implications of relapse were evaluated in sensitivity analysis; (6) response to treatment was conditional on genotype; (7) the rate of liver disease progression in the absence of treatment was independent of genotype; (8) minor adverse effects of treatment resulted in additional costs and a temporary decrease in quality of life, whereas major toxicity due to treatment resulted in treatment discontinuation; (9) patients were eligible to receive 4 sequential regimens of HAART for HIV78,79; and (10) coinfected patients with decompensated cirrhosis or HCC were not eligible for liver transplantation. Alternative assumptions were evaluated in sensitivity analysis.
The variable estimates and plausible ranges used in the base case analysis are shown in Table 1.70- 109110- 138 A summary of selected clinical studies used to establish the plausible ranges for variables related to the relationship between HIV and HCV, and the efficacy of treatment for HCV, is available from the authors.139- 148 In HIV-uninfected patients, progression from chronic HCV to cirrhosis and HCC may take up to several decades.8,9 The risk of cirrhosis implied by cohort studies149- 153 of chronically infected patients ranges from 8% to 50% after 1 to 2 decades, although these studies are subject to referral bias because most were performed at tertiary referral centers. A much slower rate of progression has been implied from prospective cohort studies80,88,154- 159 of acutely infected patients after transfusion or during defined periods of exposure.
To estimate the probabilities of progression from compensated to decompensated cirrhosis as well as the risk of HCC and death, a series of calibration exercises was conducted using one of the largest published studies of cirrhotic patients with chronic HCV.91 First, we used the model to simulate the course of chronic HCV in an HIV-uninfected cohort and projected several clinical outcomes, including decompensated cirrhosis, HCC, and death. Second, the probabilities of disease progression were adjusted until the model outcome projections closely matched the observed data.91 Finally, these disease progression probabilities were adjusted to reflect the increased risk of advanced liver disease reported in coinfected patients.2,21- 25,27,29- 39,160- 164 In the base case, we conservatively assumed a relative risk (RR) of progression to cirrhosis of 2 compared with HIV-uninfected patients, but varied it from 1 (ie, no increased risk compared with HIV-uninfected patients) to 5 in sensitivity analysis.
The natural history of HIV disease was modeled by stratifying health states by CD4 cell counts, as was done in previous studies.138,165 To incorporate the impact of HAART, we first extrapolated average probabilities of CD4 cell decline and HIV-related mortality using published data.166- 168 Because health states were not stratified by HIV RNA level, we calibrated our simplified model to results obtained with a previously described computer-based simulation model of HIV disease that includes both HIV RNA and CD4 cell count as predictors of disease progression.101- 103 Assuming a hypothetical cohort of 1 million HIV-infected adults with a mean CD4 cell count of 350 cells/µL, the probabilities of CD4 decline and HIV-related mortality were adjusted such that projected life expectancy, QALE, and costs for both models converged.
Details of this more comprehensive HIV policy model have been published elsewhere.101- 103 Briefly, it is a state-transition model programmed in C and compiled with Visual C++ 6.0 (Microsoft Corp, Redmond, Wash) in which the risks of opportunistic infections and death are stratified by CD4 cell count and the rate of CD4 cell decline is determined by level of HIV RNA. Methods used to derive the transition probabilities for antiretroviral treatment efficacy in this model are described elsewhere101- 103 and are based on data from several clinical trials.166- 171 Data have also been incorporated regarding the initiation, discontinuation, efficacy, and toxic effects of prophylaxis against major opportunistic infections.101- 103
We assumed that the efficacy of combination regimens for chronic HCV in coinfected patients was the same as in HIV-uninfected patients, although we explored lower rates of response in sensitivity analyses.140- 148,163 We used data from several studies172- 184 to estimate a plausible range for the risk of minor and major toxic effects from HCV treatment or HAART.
The consequences of mortality and morbidity were incorporated into a single outcome measure by adjusting life expectancy for quality of life on a scale from 0 (death) to 1 (perfect health). Data were not available for the specific health states in our model, which reflect coinfection with HCV and HIV. Therefore, we assumed a multiplicative relationship using the quality weights derived for each disease separately.185,186 The quality weights for the HCV-specific health states were from published studies using the visual analog scale. We calculated utilities from these values using a rating scale transformation derived by Torrance.187 The quality weights for the HIV-specific health states were derived from recent works107- 110 based on data from the HIV Cost and Services Utilization Study.
An increasing number of studies106,111- 124,188,189 document the impact of chronic HCV on health-related quality of life. We conservatively assumed that the quality of life benefit associated with treating moderate hepatitis was captured by averting progression to cirrhosis. We explored the effect of temporary decrements in quality of life associated with treatment (due to adverse effects and medication toxic effects) for chronic HCV.172,173
We used previously published estimates for the direct medical costs associated with chronic HCV that were based on a cost accounting approach and combined unit cost estimates for office visits, hospitalizations, laboratory tests, and medications, with resource utilization frequency estimated by an expert panel.55 Drug costs were based on average wholesale prices.128,132 Because of a wide discrepancy in costs based on compounded vs separately marketed drugs, a wide plausible range was used in sensitivity analyses.63,125,130,131 To account for inflation, all costs were converted to constant dollars using the Medical Care Component of the Consumer Price Index.129
Costs of monthly HIV care were based on previously published data and reflected routine HIV care, antiretroviral drug costs, HIV RNA testing every 3 months, and resistance testing after virologic failure after the first HAART regimen.101- 103 The costs of genotypic resistance tests, CD4 tests, and HIV RNA and HCV RNA assays were obtained from the public use Clinical Diagnostic Laboratory Fee Schedule.134 Estimates were similar to other sources of costs attributable to HIV and acquired immunodeficiency syndrome.135
We compared the model's predictions of cirrhosis and mortality with data from published studies that were not used for variable estimation. For an HIV-infected cohort with mild chronic HCV, our model predicted a cumulative risk of cirrhosis after 10 years of 16.9% compared with 14.9% reported by Soto et al.37 The model predicted that 90% of deaths were attributable to HIV disease and that 5% were attributable to HCV compared with the 89% and 5%, respectively, observed by Puoti et al.17
For a cohort of 35-year-old coinfected patients (mean CD4 cell count of 350 cells/µL) with moderate HCV, the average discounted QALE was 83.8 months, and lifetime costs were $139 000 (Table 2). In patients with genotype 1, treatment for HCV provided incremental gains ranging from 6.2 to 7.8 quality-adjusted life-months compared with no therapy. Combination therapy with interferon alfa and ribavirin for 48 weeks dominated combination therapy for 24 weeks and interferon alfa alone because it was more effective and had a lower (more attractive) cost-effectiveness ratio. Compared with no therapy, its incremental cost-effectiveness ratio was $11 600 per quality-adjusted life-year (QALY). In comparison, combination therapy with pegylated interferon alfa and ribavirin for 48 weeks provided an additional 1.6 quality-adjusted months of life for a cost of $40 000 per QALY.
Treatment provided even greater QALE gains in individuals with non-1 genotypes. Combination therapy with interferon alfa and ribavirin for 24 weeks provided 12.3 quality-adjusted life-months and had an incremental cost-effectiveness ratio of $2900 per QALY compared with no therapy. Combination therapy for 48 weeks provided 1.0 additional month of life expectancy and cost $38 800 per QALY compared with a 24-week course. In comparison, pegylated interferon alfa and ribavirin for 48 weeks provided an additional 3 weeks and cost $105 300 per QALY gained.
For an otherwise identical cohort of coinfected patients with mild chronic HCV, QALE gains were lower, reflecting their overall lower risk of progression to cirrhosis. In those with genotype 1, combination therapy with interferon alfa and ribavirin for 48 weeks increased QALE by 2.2 months and cost $35 900 per QALY compared with no therapy. In comparison, pegylated interferon alfa and ribavirin therapy for 48 weeks increased QALE by 3 weeks and cost $113 100 per QALY. In those with genotypes other than 1, interferon alfa and ribavirin administration for 24 weeks increased the QALE by 4.5 months and cost $11 900 per QALY compared with no treatment. The additional clinical benefits achieved with 48 weeks of combination therapy with either regular interferon alfa or pegylated interferon alfa ranged from 2 to 3 weeks and cost $112 100 and $300 800 per QALY, respectively.
Results were most sensitive to the RR of progression to cirrhosis compared with HIV-negative patients, the ability to tolerate HAART, and the discount rate (Figure 2). Results were moderately sensitive to the long-term effectiveness and cost of treatment for HCV. General results were minimally sensitive to the direct medical costs associated with HIV disease, a potential treatment effect in nonresponders, and minor toxic effects. The impact of major toxic effects depended on assumptions made about the necessity for long-term treatment interruptions with HAART.
Figure 3 shows the relationship between the RR of progression to cirrhosis in coinfected patients with mild and moderate chronic HCV compared with HIV-uninfected patients and the incremental cost-effectiveness ratios for combination therapy compared with the next best treatment strategy. General results for patients with genotype 1 (Figure 3 A) and non-1 genotypes (Figure 3 B) are similar, although the optimal strategies for treatment differ. For patients with genotype 1, even with an RR of 1 the gains in QALE ranged from 4.04 to 5.12 months. For this conservative scenario, the incremental cost-effectiveness ratio for combination therapy with interferon alfa and ribavirin was $18 800 per QALY compared with no therapy. In comparison, treatment with pegylated interferon alfa and ribavirin for 48 weeks was $62 000 per QALY. As the RR was increased from 1 (ie, risk is no different than in HIV-uninfected patients) to 5, the incremental benefits associated with treatment increased and the cost-effectiveness ratios became more attractive. The impact on the cost-effectiveness ratios associated with treatment was most pronounced between an RR of 1 and 2, with less effect observed at RRs higher than 3. Changes in the RR had a greater effect on patients with mild HCV than with moderate HCV because the former have a lower baseline probability of disease progression.
We explored the potential implications of major toxicity resulting from the use of interferon alfa and ribavirin if such toxic effects resulted in a 50% reduction in the effectiveness of HAART (eg, secondary to a lower rate of adherence or necessity for discontinuation of HAART). Under these exploratory and hypothetical conditions, if 20% of patients experienced major toxicity resulting from 48 weeks of combination therapy with pegylated interferon alfa and ribavirin, the incremental cost-effectiveness ratio increased from $40 600 to $69 000 per QALY with genotype 1 compared with the next best strategy. In contrast, minor adverse affects from treatment had little effect on the results.
In coinfected patients with mild chronic hepatitis, results were sensitive to assumptions about the impact of treatment on quality of life. The life expectancy benefits from treating mild HCV ranged from 1 to 2 weeks, whereas the QALE benefits ranged from 2 weeks to nearly 2 months (Table 2). These results demonstrate that a substantial proportion of the clinical benefit associated with treating mild chronic HCV results from averting progression to moderate HCV, which is associated with a poorer quality of life.
For patients with moderate HCV and genotype 1, the cost-effectiveness of pegylated interferon alfa and ribavirin therapy was sensitive to assumptions about the potential quality of life benefits associated with a single weekly injection compared with the 3 weekly injections needed for regular interferon alfa. We conducted a threshold analysis to identify the quality of life decrement associated with 3 weekly subcutaneous injections that would make pegylated interferon alfa plus ribavirin the preferred strategy. We found that if the quality of life during 48 weeks of treatment was reduced by more than 10%, combination therapy with pegylated interferon alfa and ribavirin dominated conventional interferon alfa–based strategies.
We conducted an exploratory analysis for patients with CD4 cell counts below 200 cells/µL. For coinfected patients in later stages of HIV with CD4 cell counts below 200 cells/µL and with moderate HCV, the general results were similar, although all cost-effectiveness ratios were higher, reflecting the increased competing morbidity and mortality associated with HIV disease (Table 2). In sensitivity analysis, when the efficacy of HAART was increased such that life expectancy approached that of the average patient in the base case cohort, the cost-effectiveness ratios associated with HCV treatment consistently declined below $50 000 per QALY.
We also evaluated the cost-effectiveness of interferon alfa–based monotherapy in coinfected patients intolerant of ribavirin. For these patients, monotherapy with pegylated interferon alfa was the most effective option. Compared with regular interferon alfa therapy, the cost-effectiveness ratio associated with use of pegylated interferon alfa was $29 400 per QALY in patients with genotype 1 and $20 300 per QALY in patients with non-1 genotypes.
We found that for HIV-infected patients with moderate chronic HCV and a mean CD4 cell count of 350 cells/µL, treatment with combination therapy using an interferon alfa–based regimen reduced the incidence of cirrhosis and provided substantial gains in QALE. Regardless of genotype, the cost-effectiveness of interferon alfa and ribavirin therapy for patients with moderate HCV was less than $50 000 per QALY.
The incremental benefits and cost-effectiveness of pegylated interferon alfa and ribavirin therapy for 48 weeks (compared with use of regular interferon alfa and ribavirin for 24 and 48 weeks) differed between individuals with genotype 1 and non-1 genotypes. Combination therapy (pegylated interferon alfa and ribavirin) in patients with moderate HCV and genotype 1 cost less than $50 000 per QALY. In contrast, because treatment is relatively more effective in patients with non-1 genotypes, the incremental gain in QALE associated with the more costly pegylated interferon alfa, compared with regular interferon alfa and ribavirin, was relatively small. Accordingly, although the cost-effectiveness ratio of interferon alfa and ribavirin therapy for non-1 genotypes was less than $50 000 per QALY compared with no treatment, combination therapy with pegylated interferon alfa exceeded $100 000 per QALY. For all patients, regardless of genotype, if ribavirin was not tolerated, monotherapy with pegylated interferon alfa was the best option.
There is considerable uncertainty in the natural history of chronic HCV, although recent data indicate that the RR of liver disease progression seems to be increased in coinfected patients compared with HIV-uninfected patients.2,6,17,19,24- 37 We assumed an RR of 2 for progression of liver disease compared with HIV-uninfected patients, but all analyses were repeated using the more conservative assumption of an RR of 1. When we assumed that the risk of liver disease was no different than in HIV-uninfected patients, the life expectancy gains and cost-effectiveness ratios associated with treatment for moderate HCV were comparable or superior to those provided by prophylaxis for opportunistic infections. In contrast, the cost-effectiveness of treatment for mild HCV was more sensitive to assumptions about the RR of HCV progression in HIV-infected vs HIV-uninfected patients. Unless this RR was 2 or greater, the incremental cost-effectiveness ratio for combination therapy exceeded $50 000 per QALY. These results highlight the importance of obtaining better data to inform the attributable excess risk associated with HIV coinfection. The results of this analysis indicate that the information with the greatest potential value will be that providing detail on whether the RR is closer to 1 or 2 in coinfected compared with HIV-uninfected patients.
Detailed data on the interactions between the tolerance and effectiveness of HAART and treatment for HCV are not yet available, to our knowledge. Therefore, the goal of our exploratory analyses examining the implications of these interactions was to provide qualitative insight into the importance of certain variables but not to answer questions for which data are not yet available. We found that changes in HCV treatment efficacy and minor toxic effects, when varied over a wide plausible range, had a minimal effect on our major results. In contrast, there was a greater effect of major toxic effects when they resulted in a lower efficacy of HAART. Without the clinical benefits associated with HAART, patients experienced HIV disease progression before the development HCV-related end-stage liver disease; thus, they received minimal life-extending benefit from HCV treatment despite accruing its treatment costs. On the other hand, it is equally plausible that treatment for HCV could improve the probability of tolerance to HAART by reducing the risk of hepatotoxicity. If this turns out to be true, HCV treatment will provide even greater clinical benefits and be even more cost-effective. These results indicate that better information on whether HCV treatment limits or enhances tolerability to HAART should be a high priority.
This study has several additional limitations. The natural history of HCV is uncertain in HIV-uninfected patients and in HIV-infected patients undergoing HAART. The efficacy and toxic effects of HCV therapy in HIV-infected patients have only been assessed in relatively small clinical studies. There are no published data, to our knowledge, on the quality of life associated with coinfection, stratified by stage of HIV disease, that are suitable for weighting the specific health states in our model. We assumed a multiplicative relationship between the quality weights for HIV and HCV, but empiric data to inform the validity of this assumption are lacking. The quality of life benefits associated with use of pegylated interferon alfa, recently approved by the Food and Drug Association for treatment of chronic HCV, remain unclear. Our results indicate that, in theory, if HCV could be treated before an individual's need for HAART (thereby eliminating any potential negative consequences of HCV treatment on tolerance of HAART or preventing hepatotoxicity of HAART), such a strategy would likely be effective and cost-effective. It is possible that temporary interruptions in HAART due to HCV treatment toxic effects will be less detrimental than we assumed; in this case, the negative impact of toxic effects was overestimated. Our results do not address the question of whether treatment for HCV should be administered much earlier in the disease progression (eg, CD4 cell counts >500 cells/µL). Data in these patients are lacking but will be important to incorporate when available. A key attribute of a model such as this one is that as better data become available, the impact of new information can be rapidly evaluated. In the meantime, however, clinical decisions for individuals and broader public policy decisions must proceed before all uncertainties are resolved.
Evaluating the effectiveness of HCV treatment in coinfected patients requires specification of the natural history of both diseases (HIV and HCV), consideration of the heterogeneity of risk, treatment efficacy and toxic effects, and accessibility, feasibility, and affordability of medication and health care. Data are not available for all of this information, and our analysis therefore required multiple assumptions. However, even in the future, a single study will not be able to simultaneously consider all of these components and assess all possible strategies for all relevant populations. This analysis was conducted to provide qualitative and quantitative insight into the relative importance of different components of the treatment process and to investigate how results would change when values of key variables were changed. By identifying the most influential variables, these results may be used to help prioritize and guide data collection efforts. Our results suggest that the most critical variables for future research include the RR of progression in chronic HCV, the health-related quality of life in coinfected patients with mild HCV, and the ability to tolerate treatment for HIV with HAART.
Based on conservative assumptions about the natural history of HCV and treatment efficacy, coinfected patients with a CD4 cell count of at least 350 cells/µL and moderate chronic HCV should be treated with combination therapy. In patients able to tolerate combination therapy, the choice of pegylated vs standard interferon alfa (in combination with ribavirin) depends on the genotype (and likelihood of sustained treatment response to traditional interferon alfa and ribavirin) and assumptions about the quality of life decrement associated with 3 subcutaneous injections per week. Patients who are intolerant of ribavirin therapy should be treated with pegylated interferon alfa regardless of genotype.
Accepted for publication April 24, 2002.
This study was presented in part at the meeting of the Society of Medical Decision Making, Cincinnati, Ohio, September 25, 2000.
Corresponding author and reprints: Sue J. Goldie, MD, MPH, Harvard Program on the Economic Evaluation of Medical Technology, 718 Huntington Ave, Second Floor, Boston, MA 02115-5924 (e-mail: email@example.com).